EssilorLuxottica's Essilor Stellest Lens Gains FDA Approval

EssilorLuxottica announced that its Essilor Stellest lens has received market authorization from the U.S. FDA, using the De Novo pathway. This makes it the first FDA-approved spectacle lens clinically proven to slow myopia progression in children. Clinical trials demonstrate a 71% reduction in myopia progression over two years.

Francesco Milleri, CEO of EssilorLuxottica, highlighted the lens as a significant innovation in vision care. The company has been a leader in myopia research for over 40 years, aiming to deliver solutions to address the growing myopia epidemic affecting children globally. The lens will soon be available to U.S. eyecare professionals.

With myopia affecting 1 in 4 children in North America, Essilor Stellest offers a critical solution in mitigating its progression and improving eye health outcomes.